Pd Therapeutic Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task ID: pd001
Created: 2026-03-06
Slot: 5 (Mechanistic Models)
Status: P0
This page systematically scores and ranks every known Parkinson's Disease (PD) therapeutic approach using a 7-dimension rubric (max 70 points). The goal is to provide an evidence-based framework for prioritizing research and development efforts. Each approach is scored 0-10 per dimension with justification drawn from clinical trial data, mechanistic understanding, and real-world evidence.
The scoring rubric:
| Dimension |
Description |
10 = Best |
| Mechanistic Clarity |
How well we understand WHY this works at molecular level |
Complete pathway mapped, validated targets |
| Clinical Evidence |
Human data supporting efficacy |
Phase 3 positive with motor + biomarker endpoints |
| Delivery Feasibility |
Can we get the drug to the right brain region at therapeutic dose? |
Approved delivery, proven brain exposure |
| Safety Profile |
Risk/benefit for a chronic disease in elderly patients |
Well-tolerated, minimal monitoring needed |
| Combinability |
Can this be combined with other approaches for additive/synergistic effect? |
Orthogonal mechanism, proven combo safety |
| Timeline to Impact |
How soon could this meaningfully help patients? |
Available now or Phase 3 with clear path |
| Addresses Root Cause |
Does this treat symptoms, slow progression, or actually halt/reverse the disease? |
Reverses pathology and restores function |
| Rank |
Approach |
Mechanistic Clarity |
Clinical Evidence |
Delivery Feasibility |
Safety Profile |
Combinability |
Timeline to Impact |
Addresses Root Cause |
Total |
| 1 |
Levodopa/Carbidopa/Entacapone |
10 |
10 |
10 |
8 |
9 |
10 |
2 |
59 |
| 2 |
MAO-B Inhibitors (Selegiline/Rasagiline/Safinamide) |
10 |
10 |
10 |
9 |
9 |
10 |
2 |
58 |
| 3 |
Dopamine Agonists (Pramipexole/Ropinirole) |
9 |
9 |
9 |
8 |
9 |
9 |
2 |
55 |
| 4 |
COMT Inhibitors (Entacapone/Opicapone) |
9 |
9 |
10 |
8 |
9 |
9 |
2 |
56 |
| 5 |
Deep Brain Stimulation (DBS) |
9 |
10 |
7 |
7 |
8 |
9 |
1 |
51 |
| 6 |
Exercise & Lifestyle Intervention |
8 |
9 |
10 |
10 |
9 |
8 |
3 |
57 |
| 7 |
GLP-1 Agonists (Exenatide/Liraglutide) |
7 |
7 |
8 |
9 |
8 |
6 |
5 |
50 |
| Rank |
Approach |
Mechanistic Clarity |
Clinical Evidence |
Delivery Feasibility |
Safety Profile |
Combinability |
Timeline to Impact |
Addresses Root Cause |
Total |
| 8 |
AAV-AADC Gene Therapy |
7 |
6 |
6 |
7 |
7 |
5 |
6 |
44 |
| 9 |
AAV-GAD Gene Therapy |
7 |
6 |
6 |
7 |
7 |
5 |
6 |
44 |
| 10 |
Cell Replacement Therapy (iPSC Dopaminergic) |
6 |
5 |
5 |
6 |
6 |
4 |
8 |
40 |
| 11 |
Alpha-Synuclein Immunotherapy (Cinpanemab/Prasinezumab) |
7 |
5 |
7 |
8 |
7 |
5 |
6 |
45 |
| 12 |
LRRK2 Inhibitors (Denileukin/BIIB122) |
7 |
5 |
7 |
8 |
7 |
5 |
5 |
44 |
| 13 |
Focused Ultrasound Thalamotomy |
8 |
7 |
6 |
7 |
6 |
7 |
1 |
42 |
| 14 |
Amantadine |
7 |
8 |
9 |
6 |
7 |
8 |
1 |
46 |
| 15 |
Anticholinergics (Trihexyphenidyl) |
8 |
8 |
9 |
5 |
6 |
9 |
1 |
46 |
| 16 |
Iron Chelators (Deferoxamine/Deferasirox) |
6 |
4 |
7 |
7 |
6 |
4 |
5 |
39 |
| 17 |
Calcium Channel Blockers (Isradipine) |
5 |
4 |
8 |
8 |
6 |
4 |
4 |
39 |
| 18 |
Masitinib (Anti-inflammatory) |
6 |
5 |
7 |
7 |
7 |
5 |
4 |
41 |
| 19 |
Dietary Interventions (Ketogenic/Mediterranean) |
6 |
5 |
10 |
9 |
8 |
5 |
3 |
46 |
| 20 |
Sigma-1 Agonists |
5 |
4 |
7 |
7 |
6 |
4 |
5 |
38 |
| 21 |
Sleep Optimization |
7 |
6 |
10 |
9 |
8 |
6 |
3 |
49 |
| 22 |
Microbiome Modulation |
4 |
3 |
8 |
8 |
6 |
3 |
4 |
36 |
| Rank |
Approach |
Mechanistic Clarity |
Clinical Evidence |
Delivery Feasibility |
Safety Profile |
Combinability |
Timeline to Impact |
Addresses Root Cause |
Total |
| 23 |
GBA Gene Therapy |
6 |
3 |
5 |
6 |
5 |
3 |
6 |
34 |
| 24 |
PINK1/Parkin Mitophagy Activators |
5 |
2 |
5 |
6 |
5 |
2 |
6 |
31 |
| 25 |
Combination Therapy (Multi-target) |
6 |
4 |
6 |
6 |
4 |
4 |
5 |
35 |
%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#4CAF50', 'edgeLabelBackground':'#ffffff', 'tertiaryColor': '#f5f5f5'}}}%%
gantt
title PD Therapeutic Approaches - Timeline to Impact
dateFormat X
axisFormat %s
section Available Now
Levodopa/Carbidopa/Entacapone :active, 10, 10
MAO-B Inhibitors :active, 10, 10
COMT Inhibitors :active, 10, 10
Dopamine Agonists :active, 9, 10
Exercise & Lifestyle :active, 10, 10
Amantadine :active, 9, 10
section Near-Term (2-5 years)
GLP-1 Agonists : 7, 8
Alpha-Syn Immunotherapy : 6, 7
LRRK2 Inhibitors : 6, 7
DBS : 8, 9
Sleep Optimization : 7, 8
section Medium-Term (5-10 years)
Gene Therapy (AADC/GAD) : 5, 6
Cell Replacement Therapy : 4, 5
Iron Chelators : 4, 5
Masitinib : 5, 6
section Long-Term (>10 years)
Mitophagy Activators : 2, 3
Microbiome Modulation : 3, 4
GBA Gene Therapy : 3, 4
%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#2196F3'}}}%%
xychart-beta
title "Top 10 PD Approaches - Total Score"
x-axis ["Levodopa", "MAO-B", "Exercise", "COMT", "Dopamine Ag", "DBS", "GLP-1", "Anticholin", "Amantadine", "Diet"]
y-axis "Score (0-70)" 0 --> 70
bar [59, 58, 57, 56, 55, 51, 50, 46, 46, 46]
- Mechanistic Clarity (10): Complete understanding of dopamine synthesis pathway, aromatic amino acid decarboxylation, and COMT inhibition mechanism.
- Clinical Evidence (10): Gold standard since 1960s; extensive Phase 3 data across thousands of patients.
- Delivery Feasibility (10): Oral administration; excellent CNS penetration via L-amino acid transport.
- Safety Profile (8): Well-characterized side effects (dyskinesia, on/off phenomena); manageable in most patients.
- Combinability (9): Can be combined with all other PD medications; foundational to all combination regimens.
- Timeline to Impact (10): Available immediately; standard of care.
- Addresses Root Cause (2): Replaces dopamine but does not slow disease progression or address alpha-synuclein pathology.
- Mechanistic Clarity (10): Well-understood mechanism of dopamine breakdown inhibition in the brain.
- Clinical Evidence (10): Multiple Phase 3 trials (ADAGIO, TEMPO, SEQUEL) showing motor benefits and potential disease modification.
- Delivery Feasibility (10): Oral delivery; good brain penetration.
- Safety Profile (9): Generally well-tolerated; dietary restrictions for selegiline/rasagiline at higher doses.
- Combinability (9): Works synergistically with levodopa; reduces "off" time.
- Timeline to Impact (10): FDA-approved; widely available.
- Addresses Root Cause (2): Symptomatic only; no evidence of disease modification.
- Mechanistic Clarity (8): Neuroplasticity, BDNF elevation, mitochondrial biogenesis mechanisms increasingly understood.
- Clinical Evidence (9): Multiple RCTs (PDSAFE, EXERT, SPARX) showing motor and non-motor benefits.
- Delivery Feasibility (10): Non-invasive; accessible to most patients.
- Safety Profile (10): Excellent safety; minimal adverse events.
- Combinability (9): Can be combined with all pharmacological treatments.
- Timeline to Impact (8): Available immediately with proper guidance.
- Addresses Root Cause (3): May have disease-modifying effects via neuroplasticity; evidence growing but not definitive.
- Mechanistic Clarity (9): Peripheral dopamine metabolism inhibition well-characterized.
- Clinical Evidence (9): Long-term extension studies support efficacy.
- Delivery Feasibility (10): Oral administration; complementary to levodopa.
- Safety Profile (8): Well-tolerated; discoloration of body fluids with entacapone.
- Combinability (9): Standard combination with levodopa/carbidopa.
- Timeline to Impact (9): FDA-approved; widely used.
- Addresses Root Cause (2): Purely symptomatic treatment.
- Mechanistic Clarity (9): Dopamine receptor activation pathways well-understood.
- Clinical Evidence (9): Extensive clinical trial data supporting efficacy.
- Delivery Feasibility (9): Oral and transdermal (rotigotine patch) options.
- Safety Profile (8): Side effects include impulse control disorders, hallucinations, somnolence.
- Combinability (9): Used in combination with levodopa.
- Timeline to Impact (9): Available now.
- Addresses Root Cause (2): Symptomatic treatment only.
- Symptomatic control: Levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists provide excellent motor symptom control.
- Non-pharmacological: Exercise is underutilized but has strong evidence for both symptomatic and potentially disease-modifying effects.
- Disease modification: No current therapy definitively slows or reverses disease progression.
- Non-motor symptoms: Less evidence for treating cognitive decline, autonomic dysfunction, and sleep disorders.
- Neuroprotection: All approaches score low (1-3) on "Addresses Root Cause" dimension.
- GLP-1 agonists: Show promise in Phase 2; disease-modifying potential via anti-inflammatory and anti-apoptotic mechanisms.
- Gene therapy: AAV-AADC and AAV-GAD show benefit in Phase 1/2; potential for long-term effect.
- Cell replacement: iPSC-derived dopaminergic neurons in early clinical trials; could potentially restore function.
- Alpha-synuclein immunotherapy: Targeting the core pathological protein; Phase 2/3 trials ongoing.
- Best combinations: Levodopa + MAO-B inhibitor + COMT inhibitor (maximizes dopaminergic tone)
- Emerging combos: GLP-1 + standard of care; gene therapy + immunotherapy
The study of Pd Therapeutic Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Poewe W, et al. (2017). Parkinson disease. Nat Rev Dis Primers. DOI:10.1038/nrdp.2017.13
- Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet. DOI:10.1016/S0140-6736(1461393-3
- Connolly BS, Lang AE. (2014). Pharmacological management of Parkinson disease. JAMA. DOI:10.1001/jama.2014.3654
- Schapira AHV, et al. (2019). Novel pharmacological targets for Parkinson disease. Nat Rev Neurol. DOI:10.1038/s41582-019-0241-0
- Athauda D, Foltynie T. (2016). Glucagon-like peptide 1 receptor agonists and neuroprotection in Parkinson's disease. Lancet Neurol. DOI:10.1016/S1474-4422(1630139-9
- Bartus RT, et al. (2013). Beyond the 20th century: Gene therapy for neurodegenerative disorders. Ann Neurol. DOI:10.1002/ana.23978
- Stoker TB, Barker RA. (2020). Cell therapy for Parkinson's disease: a stepwise approach. J Parkinsons Dis. DOI:10.3233/JPD-202113
- Jankovic J, Tan EK. (2020). Parkinson's disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. DOI:10.1136/jnnp-2019-322338
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 34%